This is a double-blinded randomized placebo controlled trial investigating the role of upstream 80mg Atorvastastin-calcium in patients undergoing percutaneous intervention for acute STEMI.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
120
Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.
Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
The Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, United States
Major adverse cardiovascular event (MACE) defined as cardiovascular death, MI, or target revascularization 30 days post percutaneous intervention.
Time frame: 15 and 30 days post revascularization
Any increase in mean peak values of CK-MB, troponin I and myoglobin greater than twice the upper limit after intervention.
Time frame: 15 and 30 days post revascularization
Any occurrence of major adverse cardiac events defined as death, MI, congestive heart failure, cardiogenic shock or need for unplanned revascularization within 24 hours after procedure or need for emergent CABG.
Time frame: 15 and 30 days post revascularization
Symptomatic side effects of current statin medication as described by adverse effects on consent form.
Time frame: Immediately post revascularization to 30 days.
Modified Coronary Revascularization Outcome Questionnaire (CROQ-PTCA)
Time frame: 15 and 30 days post revascularization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.